Dublin–(business wire)–“Global Market for Insulin Drugs and Delivery Technologies” Report Added of ResearchAndMarkets.com Recruitment.
The present report provides an in-depth look at the market for insulin drugs and delivery technologies. This report uses data from 2021, estimates from 2022, compound annual growth rate forecasts to 2027 (forecast period 2022-2027), and regional markets for insulin drugs and delivery technologies to analyze the Analyze market trends for drugs and delivery technologies.
Along with an in-depth analysis of the competitive landscape, the report highlights current and future market potential for insulin drugs and delivery technologies. Regulatory scenarios, drivers, limitations and opportunities are covered in our latest report. The report also covers market forecasts to 2026 and market shares of key market players.
Insulin drugs and delivery technologies are used in the management of type 1 and type 2 diabetes. Convenient insulin delivery devices such as smartpens can help diabetics optimize blood sugar control and minimize the risk of related health problems. Advanced insulin delivery devices improve patient compliance.
Traditional syringes and insulin pumps have been replaced with reusable, disposable insulin pens. This is due to the latter’s portability, increased dosing accuracy, built-in memory, large doses, and ease of use. There were no major breakthroughs in conventional syringes and pumps.
Major manufacturers of insulin delivery devices include Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG. Leading manufacturers of modern insulin and human insulin include Sanofi, Eli Lilly, Novo Nordisk, Boehringer Ingelheim International GmbH, Biocon and Beatrice.
Market growth is attributed to factors such as increasing incidence of diabetes, new insulin drugs and delivery technologies. The global insulin drug and delivery technology market is segmented by device type, insulin type, and region.
In this report, the market is segmented based on device type, insulin type, and geographical region. Device types include syringes, insulin pens, insulin pumps, and smart pens. Types of insulin include long-acting, rapid-acting, premixed, intermediate-acting, and short-acting insulins.
Geographic regions covered include North America, Europe, Asia Pacific, and the rest of the world (RoW). Individual countries covered include the United States, Germany, United Kingdom, Italy, France, Japan, China, and India.
Leading manufacturers of modern insulin and insulin delivery devices including Sanofi, Eli Lilly, Novo Nordisk, Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG, and B. Braun Melsungen Descriptive company profile AG
What is included in the report
24 data tables and 31 additional tables
Latest Review of the Global Market for Insulin Drugs and Delivery Technologies
Analysis of global market trends, including historical market revenues (sales data) for 2020 and 2021, estimates for 2022, and compound annual growth rate (CAGR) forecasts to 2027
Highlights of the current state of the insulin drug and delivery industry structure, new technical updates and issues surrounding insulin pens and syringes, ongoing research activities, and regulatory and pricing scenarios
Estimation of actual market size and market forecast for insulin drugs and delivery technologies, and corresponding market share analysis by device type, insulin type, and geographical region
Updates on major merger and acquisition transactions, partnerships, collaborations and other strategic alliances within the insulin pharmaceutical and delivery technology industry
Analysis of market opportunities with a holistic review of Porter’s Five Forces analysis model considering both micro- and macro-environmental factors prevailing in the market
Identification of key stakeholders and analysis of the competitive landscape based on recent developments and segment revenues
Chapter 1; Introduction
1.1 Overview of insulin
1.2 Overview of Diabetes
1.2.1 Disease symptoms and risk factors
1.2.2 Epidemiology and economic burden
1.3 Research Goals and Objectives
1.4 Reasons for doing this research
1.5 What’s new in this update?
1.6 Scope of report
1.7 Sources of information
1.9 Geographic breakdown
1.10 Analyst Qualifications
1.11 Custom Research
1.12 Related research report
Chapter 2. Summary and Highlights
Chapter 3 Market Dynamics
3.1 Market Driver
3.1.1 Rising Diabetes Prevalence
3.1.2 Smart Insulin Drug Delivery Technology
3.1.3 Painless insulin drug delivery technology
3.2 Market Constraints
3.2.1 Product recall
3.3 Market Opportunities
3.3.1 Inorganic strategies of market players
Chapter 4 Market Overview
4.1 Market Insights
4.2 Current Market Trends
4.2.1 Recent Product Introduction
4.2.2 Recent Strategic Alliances
4.3 Future outlook
Chapter 5 Regulatory Landscape and Redemption Scenarios
5.1 Regulatory situation
5.1.1 US regulations for medical devices
5.1.2 U.S. Drug Regulation
5.1.3 European regulations for medical devices
5.1.4 European regulations on medicinal products
5.1.5 Asia-Pacific regulations on medical devices
5.2 Redemption Scenario
5.2.1 Overview of prices and redemptions
5.2.2 Medical device pricing and reimbursement
5.2.3 Pharmaceutical pricing and reimbursement
5.3.1 Insurance for diabetes emergencies
Chapter 6 Impact of Covid-19 on Market
6.2 Covid-19 crisis
6.2.1 Market Impact of Insulin Drugs and Delivery Technologies
6.2.2 Covid-19 measures
Chapter 7 Market Breakdown by Device Type
7.1 Insulin delivery technology
7.1.2 Insulin pen
7.1.3 Insulin pump
8. Market Breakdown by Insulin Type
8.1.1 Structure of insulin
8.1.2 Insulin biosynthesis
8.1.3 Types of insulin
Chapter 9 Regional Market Breakdown
9.1.1 North America
9.1.3 Asia Pacific
9.1.4 Other countries
Chapter 10 Market Opportunity Analysis
10.1 Analysis of Porter’s Five Forces
10.1.1 Threat of new entrants
10.1.2 Threat of substitutes
10.1.3 Bargaining power of suppliers
10.1.4 Bargaining Power of Buyers
10.1.5 Degree of competition
Chapter 11 Competitive Environment
Chapter 12 Company Profile
12.1 Major Companies
B. Braun Melsungen AG
Becton, Dickinson and Co.
Boehringer Ingelheim International GmbH
Eli Lilly and Co.
F. Hoffmann La Roche
Medtronic Co., Ltd.
Novo Nordisk A/S
Beatrice Co., Ltd.
Ypsomed Holding AG
Emperra GmbH E-Health Technologies
Insulet Co., Ltd.
Nanopath Technologies Co., Ltd.
Nipro Medical Co., Ltd.
Owen Mumford Co.
Tandem Diabetes Care Co., Ltd.
For more information on this report, please visit https://www.researchandmarkets.com/r/paod2q.